Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease down syndrome
Comorbidity C0023418|leukemia
Sentences 37
PubMedID- 21592571 Cd7-positive acute myelomonocytic leukemia with trisomy 21 as a sole acquired chromosomal abnormality in two adolescents.
PubMedID- 25887863 Transient abnormal myelopoiesis (tam) and myeloid leukemia associated with down syndrome (ml of ds) have morphologically indistinguishable blasts.
PubMedID- 24396488 The current report presents the first case of saa preceding acute monocytic leukemia (aml-m5) with acquired trisomy 21. written informed consent was obtained from the patient’s family.
PubMedID- 25545182 Neuropsychological late effects of treatment for acute leukemia in children with down syndrome.
PubMedID- 22776818 Clinical characteristics and outcome of refractory/relapsed myeloid leukemia in children with down syndrome.
PubMedID- 25302938 Acute megakaryoblastic leukemia associated with trisomy 21 demonstrates a distinct immunophenotype.
PubMedID- 22392565 Background: children who are treated for myeloid leukemia associated with down syndrome (ds) experience superior survival compared with children who have myeloid leukemia without ds.
PubMedID- 20692111 [fetal hepatosplenomegaly in the third trimester: a sign of leukemia in fetuses with down syndrome].
PubMedID- 22459425 Solid mass tumors are not as common as leukemia in individuals with down syndrome.
PubMedID- 24222333 Acute lymphoblastic leukemia in children with down syndrome: a retrospective analysis from the ponte di legno study group.
PubMedID- 22281466 Cases of malignant tumors other than leukemia, which are associated with down syndrome, are extremely rare.
PubMedID- 25932450 A case of pentasomy 21 with two isochromosome 21s in acute megakaryoblastic leukemia associated with down syndrome.
PubMedID- 25499068 Immune-related conditions and acute leukemia in children with down syndrome: a children's oncology group report.
PubMedID- 25231553 Prognosis and management of acute myeloid leukemia in patients with down syndrome.
PubMedID- 24962331 Background: most down syndrome children with acute myeloid leukemia (ds-aml) have an overall excellent prognosis, however, patients who suffer an induction failure or relapse, have an extremely poor prognosis.
PubMedID- 26481183 Background: on the basis of results of previous japanese trials for myeloid leukemia in down syndrome (ml-ds), the efficacy of risk-oriented therapy was evaluated in the japanese pediatric leukemia/lymphoma study group aml-d05 study.
PubMedID- 22937757 In particular, the somatic mutation of the gata1 gene, which leads to the production of n-terminally truncated gata1, contributes to the genesis of transient myeloproliferative disorder and acute megakaryoblastic leukemia in infants with down syndrome.
PubMedID- 20007548 The transient myeloproliferative disorder and acute megakaryocytic leukemia associated with down syndrome are uniquely associated with mutations in the transcription factor gata1; however, the identity of trisomic genes on chromosome 21 that predispose to these hematologic disorders remains unknown.
PubMedID- 23467713 One case of acute megakaryoblastic leukemia (amkl) with trisomy 21, trisomy 14 and unmutated gata1 gene in a phenotypically normal girl was reported.
PubMedID- 22150305 Myeloid leukemia in down syndrome.
PubMedID- 23467128 Outcome of transplantation for acute myelogenous leukemia in children with down syndrome.
PubMedID- 22513796 [gata1-mutation associated leukemia in children with trisomy 21 mosaic].
PubMedID- 20418240 Results: overall, 468 courses of methotrexate (1-5 g/m(2)) were given to 44 acute lymphoblastic leukemia patients with down syndrome and to 87 acute lymphoblastic leukemia patients without down syndrome.
PubMedID- 24391118 Outcome of transplantation for acute lymphoblastic leukemia in children with down syndrome.
PubMedID- 24991719 There were 42 cases of congenital leukemia associated with down syndrome (ds) and 39 of these cases presented features of acute myeloid leukemia (aml)-m7.
PubMedID- 21557456 Background: the aim of the jcclsg aml 9805 down study was to evaluate the effect of continuous and high-dose cytarabine combined chemotherapy on the survival outcome of acute myeloid leukemia (aml) with down syndrome (ds).
PubMedID- 24744653 Although it was reported that jak2 v617f mutation is absent in childhood all, rare mutations have been reported, especially in down syndrome patients with acute leukemia [4,5,6,7,8,9].
PubMedID- 25361478 Acute megakaryoblastic leukemia associated with trisomy 21 demonstrates a distinct immunophenotype.
PubMedID- 22942569 Transient leukemia in down syndrome: report of two cases with review of literature.
PubMedID- 22072402 High frequency of btg1 deletions in acute lymphoblastic leukemia in children with down syndrome.
PubMedID- 25266042 Acute megakaryoblastic leukemia with acquired trisomy 21 and gata1 mutations in phenotypically normal children.
PubMedID- 23874683 Furthermore, pediatric down syndrome (ds) patients with acute megakaryocytic leukemia (amkl), whose blast cells almost universally harbor somatic mutations in exon 2 of the transcription factor gene gata1, demonstrate increased overall survival relative to non-ds pediatric patients, suggesting a potential role for gata1 in chemotherapy response.
PubMedID- 22113227 Hematological disorders and leukemia in children with down syndrome.
PubMedID- 23980066 Development of acute megakaryoblastic leukemia in down syndrome is associated with sequential epigenetic changes.
PubMedID- 25587735 Approximately 20%-30% of tam survivors are at risk of development of acute myeloid leukemia (myeloid leukemia associated with down syndrome, ml-ds).
PubMedID- 20595099 Acute leukemia in children with down syndrome.
PubMedID- 20113894 Myeloid leukemia in children with down syndrome is preceded by a preleukemic clone (transient leukemia or transient myeloproliferative disorder), which may disappear spontaneously, but may also need treatment in case of severe symptoms.

Page: 1